Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ODE (Office of Device Evaluation) adds third deputy director in reorganisation:

This article was originally published in Clinica

Executive Summary

A reorganisation is in store for the Office of Device Evaluation (ODE) at the US FDA's Center for Devices and Radiological Health now that Susan Alpert has left to work at the FDA's food centre. The agency is advertising for a third deputy director to assist the new director, who has not yet been appointed. Dr Alpert shared the oversight responsibilities for the centre's six review divisions with Kimber Richter, deputy director for science and regulatory policy. The other deputy, Phil Phillips, handled regulatory matters. By adding a second clinical deputy, CDRH director David Feigal aims to relieve the next ODE director of some of the workload. ODE is responsible for product reviews.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT080044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel